Kaleido announced that it has closed $101 million in an oversubscribed Series C financing. Several new investors participated in the financing, including a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Fidelity Management and Research Company, Invus, and Rock Springs Capital, along with Kaleido’s founder, Flagship Pioneering, and a number of undisclosed investors. Kaleido plans to use the proceeds from this financing to advance its pipeline, including conducting multiple clinical studies across several therapeutic areas, and to expand its platform.
Twenty laboratory mice are poised to play an important role in preparing humans to go to Mars. A Northwestern University-led study of the microbiome in space is one of five science investigations scheduled to launch Friday, June 29, on board the SpaceX Dragon and head for the International Space Station (ISS).
Evelo (Nasdaq:EVLO) announced that it has been added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes as part of Russell Investments’ annual reconstitution that took place after market close on 6/22/2018.
IBT has previously announced its plan to start the phase 3 study in the first half of 2018. Preparations for the study have taken slightly longer than expected and the Company now plans to initiate the phase 3 study in the second half of 2018.
IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC) in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk.
To read the full article, please subscribe to our microbiome database, and you'll receive the rest of the report via email, as well as access to future reports. Other headlines include:
Topical Probiotics, Innovative Therapies for Skin Health and Well-Being
Synlogic Presents New Preclinical Data from Synthetic Biotic Immuno-Oncology Program at FOCIS 2018
Dynamic Modeling Helps Predict the Behaviors of Gut Microbes
Naturally-Derived Cancer Drugs Provide Clues As To How Microbiome May Cause Chemotherapy Resistance
